Gilead Sciences Inc. closed $6.85 short of its 52-week high ($98.90), which the company achieved on November 11th.

Gilead Sciences (GILD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $91.86 which represents a decrease of $-0.52 or -0.56% from the prior close of $92.38. The stock opened at $91.66 and touched a low ...

Gilead Sciences Inc. closed $7.05 short of its 52-week high ($98.90), which the company reached on November 11th.

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...

For years, Gilead Sciences was dead money for shareholders. That is starting to change, and a recent rally in the stock can ...

Gilead Sciences has raided Sanofi for its next chief medical officer, luring Dietmar Berger, M.D., Ph.D., away from the ...

Cantor Fitzgerald reaffirmed their neutral rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a report ...

In the Institute for Clinical and Economic Review’s (ICER’s) annual price-hike report, the U.S. | The U.S. watchdog is taking ...

At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a ...

Gilead Sciences, Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...